Evidence map›Paper›PMID 25425220›Full record

Trial reportDiabetologia2015

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.

Kwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, Alicia J Jenkins, Aimin Xu, David R Sullivan, Philip J Barter, Wei-Ting Hung, Russell S Scott, Marja-Riitta Taskinen and 2 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02704468 (FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02704468 completednot on this mapstarted 2016, after this paper: background citation

FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients

Typeobservational_patient_registrySponsorBangkok Metropolitan Administration Medical College and Vajira HospitalRan2016 to 2016Enrolled100ConditionsVascular StiffnessArmsCAVI and FGF-21
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers.International journal of biological sciences · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Kwok-Leung OngLipid Research Group, Heart Research Institute, Sydney, NSW, Australia, oklws@yahoo.com.hk.
Andrzej S Januszewski
Rachel O'Connell
Alicia J Jenkins
Aimin Xu
David R Sullivan
Philip J Barter
Wei-Ting Hung
Russell S Scott
Marja-Riitta Taskinen
Anthony C Keech
Kerry-Anne Rye
The University of Sydney · AUNational Health and Medical Research Council · AUChristchurch Hospital · NZHelsinki University Hospital · FIPharmaceutical Biotechnology (Czechia) · CZRoyal Prince Alfred Hospital · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisCirculating fibroblast growth factor 21 (FGF21) levels are often elevated in obesity, dyslipidaemia, insulin resistance and type 2 diabetes. This study investigated the relationship of plasma FGF21 levels with cardiovascular events in patients with type 2 diabetes.

methodsPlasma FGF21 levels were measured by ELISA at baseline in 9,697 individuals with type 2 diabetes participating in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. We assessed the association of FGF21 levels with the incidence of different cardiovascular outcomes over 5 years. The primary outcome was total cardiovascular disease (CVD) events and the secondary outcomes were the four individual components: coronary heart disease events, total stroke, CVD mortality and coronary and carotid revascularisation. The tertiary outcome was hospitalisation for angina pectoris.

resultsHigher baseline FGF21 levels were associated with higher risks of all cardiovascular outcome events after adjusting for the study treatment allocation (all p < 0.01). The associations remained significant for total CVD events and for coronary and carotid revascularisation after further adjusting for confounding factors, with the HR (95% CI) being 1.28 (1.10, 1.50) and 1.26 (1.01, 1.56), respectively, for the highest tertile compared with the lowest tertile (overall effect p = 0.002 and 0.007, respectively). The addition of FGF21 levels to a model including established CVD risk factors predicting total CVD events led to a non-significant increase in the C-statistic but there was a significant improvement in integrated discrimination and net reclassification. CONCLUSIONS/

interpretationHigher baseline plasma FGF21 levels were associated with higher risk of cardiovascular events in patients with type 2 diabetes.

trial registrationISRCTN64783481.

Indexed as

AgedCardiovascular DiseasesDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayFemaleFenofibrateFibroblast Growth FactorsHumansHypolipidemic AgentsMaleMiddle AgedRisk FactorsStrokeFenofibratefibroblast growth factor 21Fibroblast Growth FactorsHypolipidemic Agents

Identifiers

PMID25425220
OpenAlexW2039844480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.